| Preface | 6 |
|---|
| Contents | 8 |
|---|
| Advances in vasospasm research | 15 |
|---|
| Vasospasm pathogenies | 19 |
|---|
| Pre-vasospasm: early brain injury | 20 |
| Apoptotic markers in vasospasm after an experimental subarachnoid haemorrhage | 24 |
| Cerebrospinal fluid soluble Fas and Fas ligand levels after aneurysmal subarachnoid haemorrhage | 29 |
| Time course of oxyhemoglobin induces apoptosis in mice brain cells in vivo | 35 |
| Inhibition of c-Jun N-terminal kinase pathway attenuates cerebral vasospasm after experimental subarachnoid hemorrhage through the suppression of apoptosis | 39 |
| Oxidative stress in subarachnoid haemorrhage: significance in acute brain injury and vasospasm | 44 |
| Bilirubin oxidation products (BOXes): synthesis, stability and chemical characteristics | 53 |
| Vascular contractility changes due to vasospasm induced by periarterial whole blood and thrombocyte rich plasma | 61 |
| Vasospasm biochemistry | 63 |
|---|
| Vasospasm biochemistry | 64 |
| The roles of cross-talk mechanisms in the signal transduction systems in the pathophysiology of the cerebral vasospasm after subarachnoid haemorrhage – what we know and what we do not know | 68 |
| Subarachnoid hemorrhage induces upregulation of vascular receptors and reduction in rCBF via an ERK1=2 mechanism | 73 |
| Effect of deferoxamine-activated hypoxia inducible factor-1 on the brainstem following subarachnoid haemorrhage | 76 |
| Urgosedin downregulates mRNA expression of TNF-a in brain tissue of rats subjected to experimental subarachnoid haemorrhage | 81 |
| Nucleotide-induced cerebral vasospasm in an in vivo mouse model | 84 |
| Effects of ADPbetaS on purine receptor expression in mouse cerebral vasculature | 86 |
| Vasospasm electrophysiology | 89 |
|---|
| Electrophysiology of cerebral vasospasm | 90 |
| Cellular basis of vasospasm: role of small diameter arteries and voltage-dependent Ca2+ channels | 97 |
| Acute and chronic effects of oxyhemoglobin on voltage-dependent ion channels in cerebral arteries | 101 |
| The effect of an intracisternal nimodipine slow-release system on cerebral vasospasm after experimental subarachnoid haemorrhage in the rat | 105 |
| Cerebral vasospasm following subarachnoid haemorrhage is completely prevented by L-type calcium channel antagonist in human | 110 |
| Vasospasm pharmacology | 114 |
|---|
| Vasospasm pharmacology | 115 |
| Endothelin-converting enzyme inhibitor versus cerebrovasospasm | 119 |
| A pharmacokinetic study of clazosentan in patients with aneurysmal subarachnoid haemorrhage | 124 |
| Pharmacokinetic and pharmacodynamic aspects of the interaction between clazosentan and nimodipine in healthy subjects | 126 |
| Attenuation of intercellular adhesion molecule-1 and cerebral vasospasm in rabbits subjected to experimental subarachnoid haemorrhage by CGS 26303 | 130 |
| The effect of 17b-estradiol in the prevention of cerebral vasospasm and endothelin-1 production after subarachnoid haemorrhage | 133 |
| Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH | 137 |
| An adenosine A1 receptor agonist preserves eNOS expression and attenuates cerebrovasospasm after subarachnoid haemorrhage | 146 |
| Vasospasm molecular biology | 151 |
|---|
| Gene transfer after subarachnoid hemorrhage: a tool and potential therapy | 152 |
| Direct protein transduction method to cerebral arteries by using 11R: new strategy for the treatment of cerebral vasospasm after subarachnoid haemorrhage | 155 |
| Endothelial nitric oxide synthase-11R protein therapy for prevention of cerebral vasospasm in rats: a preliminary report | 158 |
| Microarray analysis of hemolysate-induced differential gene expression in cultured human vascular smooth muscle cells (HVSMC) | 161 |
| Vasospasm remodeling | 164 |
|---|
| Role of vascular remodeling in cerebral vasospasm | 165 |
| Possible role of tenascin-C in cerebral vasospasm after aneurysmal subarachnoid haemorrhage | 169 |
| Ecdysterone-sensitive smooth muscle cell proliferation stimulated by conditioned medium of endothelial cells cultured with bloody cerebrospinal fluid | 173 |
| The effect of oxyhemoglobin on the proliferation and migration of cultured vascular advential fibroblasts | 178 |
| The effect of oxyhemoglobin on the proliferation and migration of cultured vascular smooth muscle cells | 186 |
| Comparison of three measurement methods for basilar artery with neurological changes in rabbits subjected to experimental subarachnoid hemorrhage | 192 |
| Vasospasm diagnostic | 197 |
|---|
| Vasospasm diagnosis strategies | 198 |
| Continuous evaluation of regional oxygen saturation in cerebral vasospasm after subarachnoid haemorrhage using INVOS, portable near infrared spectrography | 201 |
| Automated voxel-based analysis of brain perfusion SPECT for vasospasm after subarachnoid haemorrhage | 205 |
| Angiographic scale for evaluation of cerebral vasospasm | 210 |
| CT evaluation of late cerebral infarction after operation for ruptured cerebral aneurysm | 214 |
| Elevated intracranial pressure or subarachnoid blood responsible for reduction in cerebral blood flow after SAH | 216 |
| Magnetic resonance imaging in the canine double-haemorrhage subarachnoid haemorrhage model | 219 |
| Perfusion/diffusion-weighted imaging protocol for the diagnosis of cerebral vasospasm and management of treatment after subarachnoid haemorrhage | 224 |
| Diffusion and perfusion MRI findings with clinical correlation in patients with subarachnoid haemorrhage related vasospasm | 228 |
| Correlation of end-tidal CO2 with transcranial Doppler flow velocity is decreased during chemoregulation in delayed cerebral vasospasm after subarachnoid haemorrhage – results of a pilot study | 232 |
| A diagnostic flowchart, including TCD, Xe-CT and angiography, to improve the diagnosis of vasospasm critically affecting cerebral blood flow in patients with subarachnoid haemorrhage, sedated and ventilated | 234 |
| Basilar artery vasospasm: diagnosis and grading by transcranial Doppler | 237 |
| Predictive value of transcranial Doppler to detect clinical vasospasm in patients with aneurysmal subarachnoid haemorrhage | 240 |
| Vasospasm medical treatment | 243 |
|---|
| Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a meta-analysis of published data | 244 |
| Hypomagnesemia after ruptured middle cerebral artery aneurysms: predictive factor and pathophysiological implication | 246 |
| The role of magnesium sulfate in the treatment of vasospasm in patients with spontaneous subarachnoid haemorrhage | 248 |
| Fasudil (a rho-kinase inhibitor) may specifically increase rCBF in spastic area | 253 |
| Multimodality therapy for cerebral vasospasm after SAH: importance of intensive care and intraarterial injection of fasudil hydrochloride | 257 |
| The effect of KMUVS-1 on experimental subarachnoid haemorrhage-induced cerebrovasospasm | 260 |
| Role of statins in cerebral vasospasm | 264 |
| Treatment of cerebral vasospasm with cilostazol in subarachnoid haemorrhage model | 268 |
| Ecdysterone attenuates vasospasm following experimental subarachnoid haemorrhage in rabbits | 273 |
| Vasospasm chemical surgery | 279 |
|---|
| Clot
|
